Valeant Gives Mixed Response To Potential Allergan/Salix Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant and activist investing partner Bill Ackman took opposite approaches to the news that Allergan may be pursuing Salix buyout as a defensive move to block a takeover.